MORTON DONALD L 4
4 · CANCERVAX CORP · Filed Nov 6, 2003
Insider Transaction Report
Form 4
CANCERVAX CORPCNVX
MORTON DONALD L
Director
Transactions
- Conversion
Common Stock
2003-11-04+795,455→ 795,455 total(indirect: By Trust) - Conversion
Common Stock
2003-11-04+28,409→ 4,287,213 total(indirect: By Trust) - Conversion
Common Stock
2003-11-04+98,814→ 98,814 total(indirect: By OncoVac, Inc.) - Conversion
Common Stock
2003-11-04+3,767,393→ 3,767,393 total(indirect: By Trust) - Conversion
Common Stock
2003-11-04+491,411→ 4,258,804 total(indirect: By Trust) - Conversion
Series A Preferred Stock
2003-11-04−98,814→ 0 total(indirect: By OncoVac, Inc.)Exercise: $10.12→ Common Stock (98,814 underlying) - Conversion
Series C Preferred Stock
2003-11-04−28,409→ 0 total(indirect: By Trust)Exercise: $8.84→ Common Stock (28,409 underlying) - Conversion
Junior Preferred Stock
2003-11-04−3,767,393→ 0 total(indirect: By Trust)Exercise: $4.40→ Common Stock (3,767,393 underlying) - Conversion
Junior Preferred Stock
2003-11-04−795,455→ 0 total(indirect: By Trust)Exercise: $4.40→ Common Stock (795,455 underlying) - Conversion
Series A Preferred Stock
2003-11-04−491,411→ 0 total(indirect: By Trust)Exercise: $10.12→ Common Stock (491,411 underlying)
Footnotes (5)
- [F1]Not applicable to this transaction.
- [F2]By Donald L. Morton, M.D., Grantor Retained Annuity Trust, dated September 6, 2002. The reporting person disclaims beneficial ownership of these securities, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose.
- [F3]By Donald L. Morton, M.D., Family Trust dated June 2, 1989.
- [F4]By OncoVac, Inc.
- [F5]Immediately convertible.